Document:

Exhibit 10.2

 

 

August 17, 2021

 

CONFIDENTIAL

 

VIA ELECTRONIC DELIVERY

 

James N. Woody, M.D., Ph.D.

Chief Executive Officer

 

Ozan Pamir

Chief Financial Officer

 

180 Life Sciences Corp.

3000 El Camino Real

Bldg. 4,
Suite 200

Palo Alto, CA 94306

 

RE: Engagement for Private Placement of Securities

 

Gentlemen:

 

This letter
agreement (the “Agreement”) confirms our agreement that 180 Life Sciences Corp., a Delaware corporation (collectively
with its owned or controlled subsidiaries, the “Company”) has engaged Maxim Group LLC (together with its affiliates,
the “Placement Agent”) to act as the Company’s exclusive Placement Agent in connection with the Company’s
proposed private placement offering (the “Offering”) of common shares or common shares and warrants (the “Securities”)
of the Company.1 The precise terms of the Securities and the gross proceeds of such Offering will be negotiated by the Placement
Agent and the Company with one or more Investors (as defined below), it being understood that, provisionally, the expected gross proceeds
of the Offering will be up to $15.0 million.

 

Upon acceptance
(indicated by your signature below), this Agreement will confirm the engagement of the Placement Agent by the Company on the terms and
conditions set forth herein.

 

		1.	Appointment.

 

(a)  Subject
to the terms and conditions of this Agreement, the Company hereby engages the Placement Agent, and the Placement Agent hereby agrees
to act, as the Company’s exclusive Placement Agent in connection with the Offering. As Placement Agent for the Offering, the
Placement Agent will advise and assist the Company in identifying one or more investors that are “accredited” within the
meaning of the U.S. federal securities laws (“Investors”) to participate in the Offering. The Company
acknowledges and agrees that the Placement Agent is only required to use its “commercially reasonable efforts” in
connection with its activities hereunder and that this Agreement does not constitute a legal or binding commitment by the Placement
Agent to purchase the Securities or introduce the Company to Investors, nor does this Agreement constitute a representation or
warranty on the part of the Placement Agent that any Offering will be consummated or any Investors introduced. The Placement Agent
will, in its sole discretion, determine the reasonableness of its efforts, and is under no obligation to perform at any level other
than what it deems reasonable. The Company retains the right to determine all of the terms and conditions of the Offering and to
accept or reject any proposals submitted to it by the Placement Agent and/or Investors in its sole and absolute discretion.

 

 

 

 

1 It is understood and acknowledged that,
in lieu of a private placement, the Company may pursue a warrant solicitation (“Warrant Solicitation”), in which case
Maxim shall act as the Company’s exclusive warrant solicitation agent. In such case Maxim shall be entitled to a fee of seven (7.0%)
of the gross proceeds received by the Company as the result of exercises of share purchase warrants during the Term.

 

Members FINRA & SIPC

300 Park Ave. * New York, NY
10022 * tel: (212) 895-3500 * (800) 724-0761 * fax: (212) 895-3783 * www.maximgrp.com

 

     

     

    

 

	180 Life Sciences Corp.

                         August 2021

                         Page 2
	

 

(b) In furtherance of the
Company’s agreement that the Placement Agent’s retention hereunder shall be exclusive, during the Term (as such term is
hereinafter defined), neither the Company nor any of its officers, directors, employees, subsidiaries, affiliates, agents or
representatives (“Representatives”) will, directly or indirectly, solicit or otherwise encourage the submission
of any proposal or offer (“Investment Proposal”) from any person or entity (including, without limitation, any
underwriter, placement agent, investment bank or financial advisor) relating to any issuance of Securities of the Company or any of
its subsidiaries or participate in any discussions regarding an Investment Proposal. The term “Investment Proposal”
shall not include (i) any investment in the equity securities of any entity other than the Company or any of its subsidiaries, (ii)
any transaction or agreement with one or more persons, firms or entities designated as a “strategic partner”, including
but not limited to Celltrion Healthcare, of the Company (a “Strategic Investment”), as determined in good faith
by the Board of Directors of the Company (the “Board”); provided, however, that each such “strategic
partner” is itself, or has a subsidiary or affiliate that is, an operating company in a business synergistic with the business
of the Company and provided further that the transaction is one in which the Company receives benefits in addition to the investment
of funds. In no event shall not a transaction in which the Company issues securities primarily for the purpose of raising capital or
to one or more persons or entities whose primary business is investing in securities be deemed a Strategic Investment, (iii)
directors, officers, paid consultants and scientific advisory board members of the Company, and (iv) Casdin Capital and Baker
Brothers Advisors LLP. Other than the parties noted in i, ii, iii and iv above, the Company will immediately cease all contacts,
discussions and negotiations with third parties regarding any Investment Proposal and, during the Term, will promptly inform that
Placement Agent of any unsolicited Investment Proposals received by the Company or its Representatives.

 

	2.	Information.

 

(a) The Company recognizes
that, in completing its engagement hereunder, the Placement Agent will be using and relying on both publicly available information
and on data, material and other information (including non-public information) furnished to Placement Agent by the Company or its
Representatives. The Company will cooperate with the Placement Agent and furnish, and cause to be furnished, to the Placement Agent
and/or Investors, any and all information and data concerning the Company, its business, financial condition and plans for the
Offering that the Placement Agent deems appropriate (including, without limitation, the Company’s strategic, business, growth,
acquisition and/or merger plans and plans for raising capital or additional financing) that is reasonably requested by the Placement
Agent and/or Investors (the “Information”), including a Private Placement Memorandum or similar documentation to
be used in connection with the Offering, if deemed appropriate by the Placement Agent (collectively, the “Private Placement
Materials”). Any Information and Private Placement Materials forwarded to prospective Investors will be in a form
acceptable to Placement Agent and its counsel. The Company represents and warrants that all Information and Private Placement
Materials, including, but not limited to, the Company’s financial statements, will be complete and correct in all material
respects and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make
the statements therein not misleading.

 

Members FINRA & SIPC

300 Park Ave. * New York,
NY 1 * tel: (212) 895-3500 * (800) 724-0761 * fax: (212) 895-3783 * www.maximgrp.com

 

     

     

    

 

	180 Life Sciences Corp.

                         August 2021

                         Page 3
	

 

(b) It is further agreed
that the Placement Agent will conduct a due diligence investigation of the Company and the Company will cooperate with such
investigation as a condition of the Placement Agent’s participation in the Offering. The Company recognizes and confirms that
the Placement Agent:

 

(i) will use and rely primarily on
the Information, the Private Placement Materials and information available from generally recognized public sources in performing the
services contemplated by this Agreement without having independently verified the same; (ii) is authorized as the Placement Agent to transmit
to any prospective Investors a copy or copies of the Information and/or Private Placement Materials, forms of subscription documents and
any other legal documentation supplied to the Placement Agent for transmission to any prospective Investors by or on behalf of the Company
or by any of the Company’s Representatives, in connection with the performance of the Placement Agent’s services hereunder
or any transaction contemplated hereby; (iii) does not assume responsibility for the accuracy or completeness of the Information or the
Private Placement Materials and such other information, if any provided to the Investors; (iv) will not make an appraisal of any assets
of the Company or of the Company generally; and (v) retains the right to continue to perform due diligence of the Company, its business
and its officers and directors during the course of the engagement.

 

(c) Until the date that is
one (1) year from the date hereof, the Placement Agent will keep all information obtained from the Company confidential except: (i)
Information which is otherwise publicly available, or previously known to or obtained by, the Placement Agent independently of the
Company and without breach of any of the Placement Agent’s agreements with the Company; (ii) the Placement Agent may disclose
such information to its officers, directors, employees, agents and representatives, and to its other advisors and financial sources
on a need to know basis only and will ensure that all such persons will keep such information strictly confidential. No such
obligation of confidentiality shall apply to information that: (i) is in the public domain as of the date hereof or hereafter enters
the public domain without a breach by the Placement Agent of this Agreement, (ii) was known or became known by the Placement Agent
prior to the Company’s disclosure thereof to the Placement Agent, (iii) becomes known to the Placement Agent from a source
other than the Company, and other than by the breach of an obligation of confidentiality owed to the Company, (iv) is disclosed by
the Company to a third party without restrictions on its disclosure, (v) is independently developed by the Placement Agent or (vi)
is required to be disclosed by the Placement Agent or its officers, members, directors, employees, agents, attorneys and to its
other advisors and financial sources, pursuant to any order of a court of competent jurisdiction or other governmental body or
self-regulatory organization or as may otherwise be required by law.

 

(d) The Company recognizes
and agrees that in order for the Placement Agent to perform properly its obligations in a professional manner, the Company will keep
the Placement Agent informed of and, to the extent practicable, permit the Placement Agent to participate in meetings and
discussions between the Company and Investors or third parties relating to the matters covered by the terms of the Placement
Agent’ engagement. If at any time during the course of the Placement Agent’s engagement, the Company becomes aware of
any material change in any of the information previously furnished to the Placement Agent, it will promptly advise the Placement
Agent of the change.

 

 (e) The Offering shall be conditioned upon, among other things, the following:

 

(i) Satisfactory completion by
the Placement Agent of its due diligence investigation and analysis of: (a) the Company’s arrangements with its officers,
directors, employees, affiliates, customers and suppliers, (b) the audited historical financial statements of the Company, and (c)
the Company’s projected financial results for the fiscal years ending December 31, 2021 through December 31, 2022;

 

(ii) The absence of adverse changes to the Company’s business, financial condition or prospects;

 

Members FINRA & SIPC

300 Park Ave. * New York,
NY 1 * tel: (212) 895-3500 * (800) 724-0761 * fax: (212) 895-3783 * www.maximgrp.com

 

     

     

    

 

	180 Life Sciences Corp.

                         August 2021

                         Page 4
	

 

(iii) 
The Company retaining a firm nationally recognized in the U.S. of independent PCAOB registered public accountants acceptable to
the Placement Agent, which will have responsibility for the preparation of the financial statements and the financial exhibits, if any,
to be included in the Private Placement Materials, and any registration statement filed with the Securities and Exchange Commission relating
to the Offering, and will continue to engage accountants of comparable quality (as may be determined in good faith by the Board or audit
committee) for a period of at least three (3) years after the initial Closing (as defined below);

 

(iv) The Company retaining a transfer agent for the Company’s
equity securities reasonably acceptable to the Placement Agent and continuing to retain a transfer agent of comparable quality for a
period of three (3) years after the initial Closing (as defined below); and

 

3. 
Compensation. As compensation for services rendered and to be rendered hereunder by Placement Agent, the Company agrees
to provide the Placement Agent with the following:

 

(a) The Company agrees to
pay the Placement Agent a cash fee payable upon Closing equal to seven percent (7.0%) of the gross proceeds received by the Company
at each Closing (the “Placement Fee”). “Closing” is defined as the receipt of gross proceeds
by the Company as a result of the Offering.

 

(b) In addition to any fees
payable to the Placement Agent hereunder, the Company shall promptly upon request from time to time and at each Closing reimburse
the Placement Agent for all expenses (including, without limitation, fees and disbursements of the Placement Agent’s counsel
and all travel and other out-of-pocket expenses) incurred by the Placement Agent in connection with its engagement hereunder up to a
maximum reimbursement of $40,000 for accountable out-of-pocket expenses. In the event the Offering takes the form of a Warrant
Solicitation, the Placement Agent’s accountable out-of-pocket expenses shall be $10,000.

 

(c) If applicable, Company
shall assist and cooperate with legal counsel to the Placement Agent in effecting a filing with respect to the public offering
contemplated by the Registration Statement to be filed in connection with the Offering (an “Issuer Filing”) with
the Financial Industry Regulatory Authority (“FINRA”) Corporate Financing Department pursuant to FINRA Rule 5110,
and the Company shall pay the filing fee required by such Issuer Filing and the fees and expenses of counsel to the Placement Agent
in connection with the Issuer Filing and clearing such filing with FINRA. The Company shall assist legal counsel to the Placement
Agent in pursuing the Issuer Filing until FINRA issues a letter confirming that it does not object to the terms of the Offering
contemplated by the Registration Statement.

 

	4.	Term of Engagement.

 

(a) This Agreement will
remain in effect for thirty (30) days or until the the final Closing of the Offering, whichever occurs earlier, after which either
party shall have the right to terminate it on thirty (30) days’ prior written notice to the other. It is acknowledged and
agreed that if the Company does a Warrant Solicitation the Placement Agent is only entitled to a commission for warrants exercised
during the tenure of the Warrant Solicitation offering period, which may be extended upon mutual agreement by and between the
Company and Maxim. The date of termination of this Agreement is referred to herein from time to time as the “Termination
Date.” The period of time during which this Agreement remains in effect is referred to herein from time to time as the
“Term.” However, if in the course of the Placement Agent’s performance of due diligence, it deems it
necessary to terminate the engagement because such due diligence reveals facts and circumstances that make it impractical to (in the
Placement Agent’s sole discretion) to proceed further with the Offering, the Placement Agent may do so immediately upon
written notice to the Company. If within nine (9) months after the Termination Date, the Company completes any public or private
offering of equity, equity-linked or debt securities or other capital raising activity of the Company with any of the Investors who
were contacted by the Placement Agent in connection with this Agreement and who the Placement Agent provided a list to the Company
within five (5) business days from Termination Date, the Company will pay to the Placement Agent upon the closing of such financing
the compensation set forth in Section 3.

 

Members FINRA & SIPC

300 Park Ave. * New York,
NY 1 * tel: (212) 895-3500 * (800) 724-0761 * fax: (212) 895-3783 * www.maximgrp.com

 

     

     

    

 

	180 Life Sciences Corp.

                         August 2021

                         Page 5
	

 

(b) Notwithstanding
anything herein to the contrary, subject to the nine (9) months’ limitation described in Section 4(a) above, the obligation to
pay the compensation and expenses described in Section 3, this Section 4, Sections 6 and 8-17 and all of Exhibit A attached, hereto
(the terms of which are incorporated by reference hereto), will survive any termination or expiration of this Agreement. The
termination of this Agreement shall not affect the Company’s obligation to pay fees to the extent provided for in Section 3
herein and shall not affect the Company’s obligation to reimburse the expenses accruing prior to such termination to the
extent provided for herein. All such fees and reimbursements due shall be paid to the Placement Agent on or before the Termination
Date (in the event such fees and reimbursements are earned or owed as of the Termination Date) or upon the closing of the Offering
or any applicable portion thereof (in the event such fees are due pursuant to the terms of Section 3 hereof).

 

5. Certain Placement Procedures.
The Company and the Placement Agent each represents to the other that it has not taken, and the Company and the Placement Agent each
agrees with the other that it will not take any action, directly or indirectly, so as to cause the Offering to fail to be entitled to
rely upon the exemption from registration afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”)
or any other exemption from registration under the Act. In effecting the Offering, the Company and the Placement Agent each agrees to
comply in all material respects with applicable provisions of the Act and any regulations thereunder and any applicable laws, rules,
regulations and requirements (including, without limitation, all U.S. state law and all national, provincial, city or other legal requirements).
The Company agrees that any representations and warranties made by it to any Investor in the Offering shall be deemed also to be made
to the Placement Agent for its benefit. The Company agrees that it shall cause any opinion of its counsel delivered to any Investors
in the Offering also to be addressed and delivered to the Placement Agent, or to cause such counsel to deliver to the Placement Agent
a letter authorizing it to rely upon such opinion.

 

6. Indemnification. The
Company agrees to indemnify Placement Agent in accordance with the indemnification and other provisions attached to the Agreement as
Exhibit A (the “Indemnification Provisions”), which provisions are incorporated herein by reference and shall
survive the termination or expiration of the Agreement.

 

7. Other
Activities. The Company acknowledges that the Placement Agent has been, and may in the future be, engaged to provide
services as an underwriter, placement agent, finder, advisor or investment banker to other companies in the industry in which the
Company is involved. Subject to Section 2 hereof, the Company acknowledges and agrees that nothing contained in this Agreement shall
limit or restrict the right of the Placement Agent or of any member, manager, officer, employee, agent or representative of the
Placement Agent, to be a member, manager, partner, officer, director, employee, agent or representative of, investor in, or to
engage in, any other business, whether or not of a similar nature to the Company’s business, nor to limit or restrict the
right of the Placement Agent to render services of any kind to any other corporation, firm, individual or association; provided that
the Placement Agent and any of its members, managers, officers, employees, agents or representatives shall not use the Information
to the detriment of the Company.

 

8. Section Left Intentionally Blank.

 

Members FINRA & SIPC

300 Park Ave. * New York,
NY 1 * tel: (212) 895-3500 * (800) 724-0761 * fax: (212) 895-3783 * www.maximgrp.com

 

     

     

    

 

	180 Life Sciences Corp.

                         August 2021

                         Page 6
	

 

9. Governing Law;
Jurisdiction; Waiver of Jury Trial. This Agreement will be governed as to validity, interpretation, construction, effect and
in all other respects by the internal law of the State of New York, without regard to the conflicts of laws principles thereof. The
Company and the Placement Agent each (i) agree that any legal suit, action or proceeding arising out of or relating to this
Agreement shall be instituted exclusively in the New York State Supreme Court, County of New York, or in the United States District
Court for the Southern District of New York, (ii) waives any objection to the venue of any such suit, action or proceeding, and the
right to assert that such forum is an inconvenient forum, and (iii) irrevocably consents to the jurisdiction of the New York State
Supreme Court, County of New York, and the United States District Court for the Southern District of New York in any such suit,
action or proceeding. Each of the Company and the Placement Agent further agrees to accept and acknowledge service of any and all
process that may be served in any such suit, action or proceeding in the New York State Supreme Court, County of New York, or in the
United States District Court for the Southern District of New York and agree that service of process upon it sent by certified mail
or private carrier (Federal Express, UPS or equivalent) to its address shall be deemed in every respect effective service of process
in any such suit, action or proceeding. The parties hereby expressly waive all rights to trial by jury in any suit, action or
proceeding arising under this Agreement.

 

10. Securities and Other
Law Compliance. The Company, at its own expense, will use its best efforts to obtain any registration, qualification or
approval required to sell any Securities under the laws (including U.S. state “blue sky” laws) of any applicable
jurisdictions (including those of any applicable non-U.S. jurisdiction or any instrumentality thereof).

 

11.
Representations and Warranties. The Company and the Placement Agent each respectively represent and warrant that: (a)
it has full right, power and authority to enter into this Agreement and to perform all of its obligations hereunder; (b) this Agreement
has been duly authorized and executed and constitutes a legal, valid and binding agreement of such party enforceable in accordance with
its terms; and (c) the execution and delivery of this Agreement and the consummation of the transactions contemplated hereby does not
conflict with or result in a breach of (i) such party’s certificate of incorporation or by-laws or (ii) any agreement to which such
party is a party or by which any of its property or assets is bound.

 

12. Parties; Assignment;
Independent Contractor; No Professional Advice. This Agreement has been and is made solely for the benefit of the Placement
Agent and the Company and each of the persons, agents, employees, officers, directors and controlling persons referred to in Exhibit
A and their respective heirs, executors, personal representatives, successors and assigns, and nothing contained in this Agreement
will confer any rights upon, nor will this Agreement be construed to create any rights in, any person who is not party to such
Agreement, other than as set forth in this section. The rights and obligations of either party under this Agreement may not be
assigned without the prior written consent of the other party hereto and any other purported assignment will be null and void. The
Placement Agent has been retained under this Agreement as an independent contractor, and it is understood and agreed that this
Agreement does not create a fiduciary relationship between the Placement Agent and the Company. The Placement Agent shall not be
considered to be the agent of the Company for any purpose whatsoever and the Placement Agent is not granted any right or authority
to assume or create any obligation or liability, express or implied, on the Company’s behalf, or to bind the Company in any
manner whatsoever. The Company further acknowledges and agrees that the Placement Agent has not been engaged to provide, and will
not provide, accounting, tax or legal advice. The Company agrees that any and all decisions, acts, actions, or omissions with
respect to the Offering shall be the sole responsibility of the Company, and that the performance by the Placement Agent of services
hereunder will in no way expose the Placement Agent to any liability for any such decisions, acts, actions or omissions of the
Company.

 

Members FINRA & SIPC

300 Park Ave. * New York,
NY 1 * tel: (212) 895-3500 * (800) 724-0761 * fax: (212) 895-3783 * www.maximgrp.com

 

     

     

    

 

	180 Life Sciences Corp.

                         August 2021

                         Page 7
	

 

13. Section Left Intentionally Blank.

 

14. Validity; Entire
Agreement. In case any term of this Agreement will be held invalid, illegal or unenforceable, in whole or in part, the
validity of any of the other terms of this Agreement will not in any way be affected thereby. This Agreement represents the full and
integrated agreement of the parties with respect to the specific matters set forth herein, and this Agreement supersedes all prior
discussions, negotiations, promises and understandings with the parties with respect to such matters.

 

15. Counterparts.
This Agreement may be executed in counterparts, which counterparts may be executed and delivered by facsimile or email/.pdf
transmission, which shall not impair the validity of such execution or delivery.

 

16. Notices.
All notices will be in writing and will be effective when delivered in person, sent by certified mail or by private carrier (Federal
Express, UPS or equivalent), or sent via facsimile or email transmission, to the party to whom it is addressed at the following
addresses or such other address as such party may advise the other in writing:

 

	To the Company: 	180 Life Sciences Corp.
	 	3000 El Camino Real 
	 	Bldg. 4, Suite 200 
	 	Palo Alto, CA 94306
	 	 
	To the Placement Agent	Maxim Group LLC
	 	300 Park Avenue 
	 	New York, NY 10022
	 	Attention: Clifford A. Teller and James Siegel, Esq. 
	 	Telephone: (212) 895-3500
	 	Facsimile: (212) 895-3783 and (212) 895-3860

 

17. Announcements.
The Company agrees that the Placement Agent shall, from and after any Closing, have the right to reference the Offering and the
Placement Agent’s role in connection therewith in the Placement Agent’s marketing materials and on its website and to
place advertisements in financial and other newspapers and journals, in each case at its own expense.

 

(Signature Page Follows)

 

Members FINRA & SIPC

300 Park Ave. * New York,
NY 1 * tel: (212) 895-3500 * (800) 724-0761 * fax: (212) 895-3783 * www.maximgrp.com

 

     

     

    

 

	180 Life Sciences Corp.

                         August 2021

                         Page 8
	

 

We are delighted
at the prospect of working with you and look forward to proceeding with the Offering. If you are in agreement with the foregoing, please
execute and return two copies of this engagement letter to the undersigned together. This Agreement may be executed in counterparts, electronic
mail and by facsimile transmission.

 

	 	 	 	Very
    truly yours,
	 	 	 	 	 
	 	 	 	Maxim
    Group LLC
	 	 	 	 
	 	 	 	/s/
    Lawrence C. Glassberg
	 	 	 	Name:  	Lawrence C. Glassberg
	 	 	 	Title:	Senior Managing
    Director, Investment Banking
	 	 	 	 	 
	 	 	 	/s/
    Clifford A. Teller
	 	 	 	Name: 	Clifford A. Teller
	 	 	 	Title:	Executive Managing
    Director of Investment Banking
	 	 	 	 	 
	Agreed
    to and accepted this 17th day of August, 2021 
 
 180 Life Sciences Corp.	 	 
	 	 	 	 	 
	/s/
    James N. Woody	 	 	 
	Name:  	James N. Woody	 	 	 
	Title: 	CEO 180 Life Sciences	 	 	 

 

Members FINRA & SIPC

300 Park Ave. * New York,
NY 1 * tel: (212) 895-3500 * (800) 724-0761 * fax: (212) 895-3783 * www.maximgrp.com

 

     

     

    

 

	180 Life Sciences Corp.

                         August 2021

                         Page 9
	

 

Exhibit A

 

INDEMNIFICATION
PROVISIONS

 

Capitalized
terms used in this Exhibit shall have the meanings ascribed to such terms in the Agreement to which this Exhibit is attached.

 

In addition
to and without limiting any other right or remedy available to the Placement Agent and the Indemnified Parties (as hereinafter defined),
the Company agrees to indemnify and hold harmless Placement Agent and each of the other Indemnified Parties from and against any and all
losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses and disbursements, and any and all actions,
suits, proceedings and investigations in respect thereof and any and all legal and other costs, expenses and disbursements in giving testimony
or furnishing documents in response to a subpoena or otherwise (including, without limitation, the costs, expenses and disbursements,
as and when incurred, of investigating, preparing, pursing or defending any such action, suit, proceeding or investigation (whether or
not in connection with litigation in which any Indemnified Party is a party)) (collectively, “Losses”), directly or indirectly,
caused by, relating to, based upon, arising out of, or in connection with, Placement Agent’s acting for the Company, including,
without limitation, any act or omission by Placement Agent in connection with its acceptance of or the performance or non-performance
of its obligations under the Agreement between the Company and Placement Agent to which these indemnification provisions are attached
and form a part, any breach by the Company of any representation, warranty, covenant or agreement contained in the Agreement (or in any
instrument, document or agreement relating thereto, including any agency agreement), or the enforcement by Placement Agent of its rights
under the Agreement or these indemnification provisions, except to the extent that any such Losses are found in a final judgment by a
court of competent jurisdiction (not subject to further appeal) to have resulted primarily and directly from the gross negligence or willful
misconduct of the Indemnified Party seeking indemnification hereunder.

 

The Company
also agrees that no Indemnified Party shall have any liability (whether direct or indirect, in contract or tort or otherwise) to the Company
for or in connection with the engagement of Placement Agent by the Company or for any other reason, except to the extent that any such
liability is found in a final judgment by a court of competent jurisdiction (not subject to further appeal) to have resulted primarily
and directly from such Indemnified Party’s gross negligence or willful misconduct.

 

These Indemnification
Provisions shall extend to the following persons (collectively, the “Indemnified Parties”): Placement Agent, its present
and former affiliated entities, managers, members, officers, employees, legal counsel, agents and controlling persons (within the meaning
of the federal securities laws), and the officers, directors, partners, stockholders, members, managers, employees, legal counsel, agents
and controlling persons of any of them. These indemnification provisions shall be in addition to any liability, which the Company may
otherwise have to any Indemnified Party.

 

If any action, suit,
proceeding or investigation is commenced, as to which an Indemnified Party proposes to demand indemnification, it shall notify the
Company with reasonable promptness; provided, however, that any failure by an Indemnified Party to notify the Company
shall not relieve the Company from its obligations hereunder. An Indemnified Party shall have the right to retain counsel of its own
choice to represent it, and the fees, expenses and disbursements of such counsel shall be borne by the Company. Any such counsel
shall, to the extent consistent with its professional responsibilities, cooperate with the Company and any counsel designated by the
Company. The Company shall be liable for any settlement of any claim against any Indemnified Party made with the Company’s
written consent. The Company shall not, without the prior written consent of Placement Agent, settle or compromise any claim, or
permit a default or consent to the entry of any judgment in respect thereof, unless such settlement, compromise or consent (i)
includes, as an unconditional term thereof, the giving by the claimant to all of the Indemnified Parties of an unconditional release
from all liability in respect of such claim, and (ii) does not contain any factual or legal admission by or with respect to an
Indemnified Party or an adverse statement with respect to the character, professionalism, expertise or reputation of any Indemnified
Party or any action or inaction of any Indemnified Party.

 

Members FINRA & SIPC

300 Park Ave. * New York,
NY 1 * tel: (212) 895-3500 * (800) 724-0761 * fax: (212) 895-3783 * www.maximgrp.com

 

     

     

    

 

	180 Life Sciences Corp.

                         August 2021

                         Page 10
	

 

In order to
provide for just and equitable contribution, if a claim for indemnification pursuant to these indemnification provisions is made but it
is found in a final judgment by a court of competent jurisdiction (not subject to further appeal) that such indemnification may not be
enforced in such case, even though the express provisions hereof provide for indemnification in such case, then the Company shall contribute
to the Losses to which any Indemnified Party may be subject (i) in accordance with the relative benefits received by the Company and its
stockholders, subsidiaries and affiliates, on the one hand, and the Indemnified Party, on the other hand, and (ii) if (and only if) the
allocation provided in clause (i) of this sentence is not permitted by applicable law, in such proportion as to reflect not only the relative
benefits, but also the relative fault of the Company, on the one hand, and the Indemnified Party, on the other hand, in connection with
the statements, acts or omissions which resulted in such Losses as well as any relevant equitable considerations. No person found liable
for a fraudulent misrepresentation shall be entitled to contribution from any person who is not also found liable for fraudulent misrepresentation.
The relative benefits received (or anticipated to be received) by the Company and it stockholders, subsidiaries and affiliates shall be
deemed to be equal to the aggregate consideration payable or receivable by such parties in connection with the transaction or transactions
to which the Agreement relates relative to the amount of fees actually received by Placement Agent in connection with such transaction
or transactions. Notwithstanding the foregoing, in no event shall the amount contributed by all Indemnified Parties exceed the amount
of fees previously received by Placement Agent pursuant to the Agreement.

 

Neither termination
nor completion of the Agreement shall affect these Indemnification Provisions which shall remain operative and in full force and effect.
The Indemnification Provisions shall be binding upon the Company and its successors and assigns and shall inure to the benefit of the
Indemnified Parties and their respective successors, assigns, heirs and personal representatives.

 

Members FINRA & SIPC

300 Park Ave. * New York,
NY 1 * tel: (212) 895-3500 * (800) 724-0761 * fax: (212) 895-3783 * www.maximgrp.comExhibit 10.3

 

REGISTRATION RIGHTS AGREEMENT

 

This Registration Rights Agreement
(this “Agreement”) is made and entered into as of August 23, 2021, between 180 Life Sciences Corp., a Delaware corporation
(the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser”
and, collectively, the “Purchasers”).

 

This Agreement is made pursuant
to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser (the “Purchase Agreement”).

 

The Company and each Purchaser
hereby agrees as follows:

 

1.  Definitions.

 

Capitalized terms used
and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement.
As used in this Agreement, the following terms shall have the following meanings:

 

“Advice”
shall have the meaning set forth in Section 6(c).

 

“Effectiveness
Date” means, with respect to the Initial Registration Statement required to be filed hereunder, the 60th calendar
day following the date hereof (or, in the event of a “full review” by the Commission, the 90th calendar day following
the date hereof) and with respect to any additional Registration Statements which may be required pursuant to Section 2(c) or Section
3(c), the 35th calendar day following the date on which an additional Registration Statement is required to be filed hereunder
(or, in the event of a “full review” by the Commission, the 60th calendar day following the date such additional
Registration Statement is required to be filed hereunder); provided, however, that in the event the Company is notified
by the Commission that one or more of the above Registration Statements will not be reviewed or is no longer subject to further review
and comments, the Effectiveness Date as to such Registration Statement shall be the fifth Trading Day following the date on which the
Company is so notified if such date precedes the dates otherwise required above, provided, further, if such Effectiveness Date falls on
a day that is not a Trading Day, then the Effectiveness Date shall be the next succeeding Trading Day.

 

“Effectiveness
Period” shall have the meaning set forth in Section 2(a).

 

“Event”
shall have the meaning set forth in Section 2(d).

 

“Event
Date” shall have the meaning set forth in Section 2(d).

 

     

     

    

 

“Filing
Date” means, with respect to the Initial Registration Statement required hereunder, the 20th calendar day following
the date hereof and, with respect to any additional Registration Statements which may be required pursuant to Section 2(c) or Section
3(c), the earliest practical date on which the Company is permitted by SEC Guidance to file such additional Registration Statement related
to the Registrable Securities.

 

“Holder”
or “Holders” means the holder or holders, as the case may be, from time to time of Registrable Securities.

 

“Indemnified
Party” shall have the meaning set forth in Section 5(c).

 

“Indemnifying
Party” shall have the meaning set forth in Section 5(c).

 

“Initial
Registration Statement” means the initial Registration Statement filed pursuant to this Agreement.

 

“Losses”
shall have the meaning set forth in Section 5(a).

 

“Plan of
Distribution” shall have the meaning set forth in Section 2(a).

 

“Prospectus”
means the prospectus included in a Registration Statement (including, without limitation, a prospectus that includes any information previously
omitted from a prospectus filed as part of an effective registration statement in reliance upon Rule 430A promulgated by the Commission
pursuant to the Securities Act), as amended or supplemented by any prospectus supplement, with respect to the terms of the offering of
any portion of the Registrable Securities covered by a Registration Statement, and all other amendments and supplements to the Prospectus,
including post-effective amendments, and all material incorporated by reference or deemed to be incorporated by reference in such Prospectus.

 

“Registrable
Securities” means, as of any date of determination, (a) all Shares, (b) all Warrant Shares then issued and issuable upon exercise
of the Warrants (assuming on such date the Warrants are exercised in full without regard to any exercise limitations therein), and (c)
any securities issued or then issuable upon any stock split, dividend or other distribution, recapitalization or similar event with respect
to the foregoing; provided, however, that any such Registrable Securities shall cease to be Registrable Securities (and the Company
shall not be required to maintain the effectiveness of any, or file another, Registration Statement hereunder with respect thereto) for
so long as (a) a Registration Statement with respect to the sale of such Registrable Securities is declared effective by the Commission
under the Securities Act and such Registrable Securities have been disposed of by the Holder in accordance with such effective Registration
Statement, (b) such Registrable Securities have been previously sold in accordance with Rule 144, or (c) such securities become eligible
for resale without volume or manner-of-sale restrictions and without current public information pursuant to Rule 144 as set forth in a
written opinion letter to such effect, addressed, delivered and acceptable to the Transfer Agent and the affected Holders (assuming that
such securities and any securities issuable upon exercise, conversion or exchange of which, or as a dividend upon which, such securities
were issued or are issuable, were at no time held by any Affiliate of the Company, as reasonably determined by the Company, upon the advice
of counsel to the Company.

 

    2

     

    

 

“Registration
Statement” means any registration statement required to be filed hereunder pursuant to Section 2(a) and any additional registration
statements contemplated by Section 2(c) or Section 3(c), including (in each case) the Prospectus, amendments and supplements to any such
registration statement or Prospectus, including pre- and post-effective amendments, all exhibits thereto, and all material incorporated
by reference or deemed to be incorporated by reference in any such registration statement.

 

“Rule 415”
means Rule 415 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.

 

“Rule 424”
means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted from time to time,
or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule.

 

“Selling
Stockholder Questionnaire” shall have the meaning set forth in Section 3(a).

 

“SEC Guidance”
means (i) any publicly-available written or oral guidance of the Commission staff, or any comments, requirements or requests of the Commission
staff and (ii) the Securities Act.

 

2.  Shelf
Registration.

 

(a)
On or prior to each Filing Date, the Company shall prepare and file with the Commission a Registration Statement covering the resale
of all of the Registrable Securities that are not then registered on an effective Registration Statement for an offering to be made on
a continuous basis pursuant to Rule 415. Each Registration Statement filed hereunder shall be on Form S-3 (except if the Company is not
then eligible to register for resale the Registrable Securities on Form S-3, in which case such registration shall be on another appropriate
form in accordance herewith, subject to the provisions of Section 2(e)) and shall contain (unless otherwise directed by at least 85% in
interest of the Holders) substantially the “Plan of Distribution” attached hereto as Annex A and substantially
the “Selling Stockholder” section attached hereto as Annex B; provided, however, that no Holder
shall be required to be named as an “underwriter” without such Holder’s express prior written consent. Subject to the
terms of this Agreement, the Company shall use its best efforts to cause a Registration Statement filed under this Agreement (including,
without limitation, under Section 3(c)) to be declared effective under the Securities Act as promptly as possible after the filing thereof,
but in any event no later than the applicable Effectiveness Date, and shall use its best efforts to keep such Registration Statement continuously
effective under the Securities Act until the date that all Registrable Securities covered by such Registration Statement (i) have been
sold, thereunder or pursuant to Rule 144, or (ii) may be sold without volume or manner-of-sale restrictions pursuant to Rule 144 and without
the requirement for the Company to be in compliance with the current public information requirement under Rule 144, as determined by the
counsel to the Company pursuant to a written opinion letter to such effect, addressed and acceptable to the Transfer Agent and the affected
Holders (the “Effectiveness Period”). The Company shall telephonically request effectiveness of a Registration Statement
as of 5:00 p.m. (New York City time) on a Trading Day. The Company shall immediately notify the Holders via facsimile or by e-mail of
the effectiveness of a Registration Statement on the same Trading Day that the Company telephonically confirms effectiveness with the
Commission, which shall be the date requested for effectiveness of such Registration Statement. The Company shall, by 9:30 a.m. (New York
City time) on the Trading Day after the effective date of such Registration Statement, file a final Prospectus with the Commission as
required by Rule 424. Failure to so notify the Holder within one (1) Trading Day of such notification of effectiveness or failure to file
a final Prospectus as foresaid shall be deemed an Event under Section 2(d).

 

(b)
 Notwithstanding the registration obligations set forth in Section 2(a), if the Commission informs the Company that all of the
Registrable Securities cannot, as a result of the application of Rule 415, be registered for resale as a secondary offering on a single
registration statement, the Company agrees to promptly inform each of the Holders thereof and use its commercially reasonable efforts
to file amendments to the Initial Registration Statement as required by the Commission, covering the maximum number of Registrable Securities
permitted to be registered by the Commission, on Form S-3 or such other form available to register for resale the Registrable Securities
as a secondary offering, subject to the provisions of Section 2(e); with respect to filing on Form S-3 or other appropriate form, and
subject to the provisions of Section 2(d) with respect to the payment of liquidated damages; provided, however, that prior
to filing such amendment, the Company shall be obligated to use diligent efforts to advocate with the Commission for the registration
of all of the Registrable Securities in accordance with the SEC Guidance, including without limitation, Compliance and Disclosure Interpretation
612.09.

 

    3

     

    

 

(c)
Notwithstanding any other provision of this Agreement and subject to the payment of liquidated damages pursuant to Section 2(d),
if the Commission or any SEC Guidance sets forth a limitation on the number of Registrable Securities permitted to be registered on a
particular Registration Statement as a secondary offering (and notwithstanding that the Company used diligent efforts to advocate with
the Commission for the registration of all or a greater portion of Registrable Securities), unless otherwise directed in writing by a
Holder as to its Registrable Securities, the number of Registrable Securities to be registered on such Registration Statement will be
reduced as follows:

 

		a.	First, the Company shall reduce or eliminate any securities to be included other than Registrable Securities;

 

		b.	Second, the Company shall reduce Registrable Securities represented by Warrant Shares (applied, in the
case that some Warrant Shares may be registered, to the Holders on a pro rata basis based on the total number of unregistered Warrant
Shares held by such Holders); and

 

		c.	Third, the Company shall reduce Registrable Securities represented by Shares (applied, in the case that
some Shares may be registered, to the Holders on a pro rata basis based on the total number of unregistered Shares held by such Holders).

 

In the event of a cutback hereunder,
the Company shall give the Holder at least five (5) Trading Days prior written notice along with the calculations as to such Holder’s
allotment. In the event the Company amends the Initial Registration Statement in accordance with the foregoing, the Company will use its
best efforts to file with the Commission, as promptly as allowed by Commission or SEC Guidance provided to the Company or to registrants
of securities in general, one or more registration statements on Form S-3 or such other form available to register for resale those Registrable
Securities that were not registered for resale on the Initial Registration Statement, as amended.

 

(d)
If: (i) the Initial Registration Statement is not filed on or prior to its Filing Date (if the Company files the Initial Registration
Statement without affording the Holders the opportunity to review and comment on the same as required by Section 3(a) herein, the Company
shall be deemed to have not satisfied this clause (i)), or (ii) the Company fails to file with the Commission a request for acceleration
of a Registration Statement in accordance with Rule 461 promulgated by the Commission pursuant to the Securities Act, within five Trading
Days of the date that the Company is notified (orally or in writing, whichever is earlier) by the Commission that such Registration Statement
will not be “reviewed” or will not be subject to further review, or (iii) prior to the effective date of a Registration Statement,
the Company fails to file a pre-effective amendment and otherwise respond in writing to comments made by the Commission in respect of
such Registration Statement within ten (10) calendar days after the receipt of comments by or notice from the Commission that such amendment
is required in order for such Registration Statement to be declared effective, or (iv) a Registration Statement registering for resale
all of the Registrable Securities is not declared effective by the Commission by the Effectiveness Date of the Initial Registration Statement,
or (v) after the effective date of a Registration Statement, such Registration Statement ceases for any reason to remain continuously
effective as to all Registrable Securities included in such Registration Statement, or the Holders are otherwise not permitted to utilize
the Prospectus therein to resell such Registrable Securities, for more than ten (10) consecutive calendar days or more than an aggregate
of fifteen (15) calendar days (which need not be consecutive calendar days) during any 12-month period (any such failure or breach being
referred to as an “Event”, and for purposes of clauses (i) and (iv), the date on which such Event occurs, and for purpose
of clause (ii) the date on which such five (5) Trading Day period is exceeded, and for purpose of clause (iii) the date which such ten
(10) calendar day period is exceeded, and for purpose of clause (v) the date on which such ten (10) or fifteen (15) calendar day period,
as applicable, is exceeded being referred to as “Event Date”), then, in addition to any other rights the Holders may
have hereunder or under applicable law, on each such Event Date and on each monthly anniversary of each such Event Date (if the applicable
Event shall not have been cured by such date) until the applicable Event is cured, the Company shall pay to each Holder an amount in cash,
as partial liquidated damages and not as a penalty, equal to the product of 1.5% multiplied by the aggregate Subscription Amount of the
Registrable Securities then owned by the Holder paid by such Holder pursuant to the Purchase Agreement, up to a maximum aggregate amount
of 5.0% multiplied by the aggregate Subscription Amount paid by such Holder pursuant to the Purchase Agreement. If the Company fails to
pay any partial liquidated damages pursuant to this Section in full within seven days after the date payable, the Company will pay interest
thereon at a rate of 18% per annum (or such lesser maximum amount that is permitted to be paid by applicable law) to the Holder, accruing
daily from the date such partial liquidated damages are due until such amounts, plus all such interest thereon, are paid in full. The
partial liquidated damages pursuant to the terms hereof shall apply on a daily pro rata basis for any portion of a month prior to the
cure of an Event.

 

    4

     

    

 

(e)
If Form S-3 is not available for the registration of the resale of Registrable Securities hereunder, the Company shall (i) register
the resale of the Registrable Securities on another appropriate form and (ii) undertake to register the Registrable Securities on Form
S-3 as soon as such form is available, provided that the Company shall maintain the effectiveness of the Registration Statement then in
effect until such time as a Registration Statement on Form S-3 covering the Registrable Securities has been declared effective by the
Commission.

 

(f)  Notwithstanding anything to the contrary contained herein, in no event shall the Company be permitted to name any Holder or affiliate
of a Holder as any Underwriter without the prior written consent of such Holder.

 

3.  Registration
Procedures.

 

In connection with the Company’s
registration obligations hereunder, the Company shall:

 

(a)
Not less than five (5) Trading Days prior to the filing of each Registration Statement and not less than one (1) Trading Day prior
to the filing of any related Prospectus or any amendment or supplement thereto (including any document that would be incorporated or deemed
to be incorporated therein by reference), the Company shall (i) furnish to each Holder copies of all such documents proposed to be filed,
which documents (other than those incorporated or deemed to be incorporated by reference) will be subject to the review of such Holders,
and (ii) cause its officers and directors, counsel and independent registered public accountants to respond to such inquiries as shall
be necessary, in the reasonable opinion of respective counsel to each Holder, to conduct a reasonable investigation within the meaning
of the Securities Act. The Company shall not file a Registration Statement or any such Prospectus or any amendments or supplements thereto
to which the Holders of a majority of the Registrable Securities shall reasonably object in good faith, provided that, the Company is
notified of such objection in writing no later than five (5) Trading Days after the Holders have been so furnished copies of a Registration
Statement or one (1) Trading Day after the Holders have been so furnished copies of any related Prospectus or amendments or supplements
thereto. Each Holder agrees to furnish to the Company a completed questionnaire in the form attached to this Agreement as Annex B
(a “Selling Stockholder Questionnaire”) on a date that is not less than two (2) Trading Days prior to the Filing Date
or by the end of the fourth (4th) Trading Day following the date on which such Holder receives draft materials in accordance
with this Section.

 

(b)
(i) Prepare and file with the Commission such amendments, including post-effective amendments, to a Registration Statement and
the Prospectus used in connection therewith as may be necessary to keep a Registration Statement continuously effective as to the applicable
Registrable Securities for the Effectiveness Period and prepare and file with the Commission such additional Registration Statements in
order to register for resale under the Securities Act all of the Registrable Securities, (ii) cause the related Prospectus to be amended
or supplemented by any required Prospectus supplement (subject to the terms of this Agreement), and, as so supplemented or amended, to
be filed pursuant to Rule 424, (iii) respond as promptly as reasonably possible to any comments received from the Commission with respect
to a Registration Statement or any amendment thereto and provide as promptly as reasonably possible to the Holders true and complete copies
of all correspondence from and to the Commission relating to a Registration Statement (provided that, the Company shall excise any information
contained therein which would constitute material non-public information regarding the Company or any of its Subsidiaries), and (iv) comply
in all material respects with the applicable provisions of the Securities Act and the Exchange Act with respect to the disposition of
all Registrable Securities covered by a Registration Statement during the applicable period in accordance (subject to the terms of this
Agreement) with the intended methods of disposition by the Holders thereof set forth in such Registration Statement as so amended or in
such Prospectus as so supplemented.

 

    5

     

    

 

(c)
If during the Effectiveness Period, the number of Registrable Securities at any time exceeds 100% of the number of shares of Common
Stock then registered in a Registration Statement, then the Company shall file as soon as reasonably practicable, but in any case prior
to the applicable Filing Date, an additional Registration Statement covering the resale by the Holders of not less than the number of
such Registrable Securities.

 

(d)
Notify the Holders of Registrable Securities to be sold (which notice shall, pursuant to clauses (iii) through (vi) hereof, be
accompanied by an instruction to suspend the use of the Prospectus until the requisite changes have been made) as promptly as reasonably
possible (and, in the case of (i)(A) below, not less than one (1) Trading Day prior to such filing) and (if requested by any such Person)
confirm such notice in writing no later than one (1) Trading Day following the day (i)(A) when a Prospectus or any Prospectus supplement
or post-effective amendment to a Registration Statement is proposed to be filed, (B) when the Commission notifies the Company whether
there will be a “review” of such Registration Statement and whenever the Commission comments in writing on such Registration
Statement, and (C) with respect to a Registration Statement or any post-effective amendment, when the same has become effective, (ii)
of any request by the Commission or any other federal or state governmental authority for amendments or supplements to a Registration
Statement or Prospectus or for additional information, (iii) of the issuance by the Commission or any other federal or state governmental
authority of any stop order suspending the effectiveness of a Registration Statement covering any or all of the Registrable Securities
or the initiation of any Proceedings for that purpose, (iv) of the receipt by the Company of any notification with respect to the suspension
of the qualification or exemption from qualification of any of the Registrable Securities for sale in any jurisdiction, or the initiation
or threatening of any Proceeding for such purpose, (v) of the occurrence of any event or passage of time that makes the financial statements
included in a Registration Statement ineligible for inclusion therein or any statement made in a Registration Statement or Prospectus
or any document incorporated or deemed to be incorporated therein by reference untrue in any material respect or that requires any revisions
to a Registration Statement, Prospectus or other documents so that, in the case of a Registration Statement or the Prospectus, as the
case may be, it will not contain any untrue statement of a material fact or omit to state any material fact required to be stated therein
or necessary to make the statements therein, in light of the circumstances under which they were made, not misleading, and (vi) of the
occurrence or existence of any pending corporate development with respect to the Company that the Company believes may be material and
that, in the determination of the Company, makes it not in the best interest of the Company to allow continued availability of a Registration
Statement or Prospectus; provided, however, that in no event shall any such notice contain any information which would constitute
material, non-public information regarding the Company or any of its Subsidiaries.

 

(e)
Use its best efforts to avoid the issuance of, or, if issued, obtain the withdrawal of (i) any order stopping or suspending the
effectiveness of a Registration Statement, or (ii) any suspension of the qualification (or exemption from qualification) of any of the
Registrable Securities for sale in any jurisdiction, at the earliest practicable moment.

 

(f) Furnish to each
Holder, without charge, at least one conformed copy of each such Registration Statement and each amendment thereto, including financial
statements and schedules, all documents incorporated or deemed to be incorporated therein by reference to the extent requested by such
Person, and all exhibits to the extent requested by such Person (including those previously furnished or incorporated by reference) promptly
after the filing of such documents with the Commission, provided that any such item which is available on the EDGAR system (or successor
thereto) need not be furnished in physical form.

 

    6

     

    

 

(g)
Subject to the terms of this Agreement, the Company hereby consents to the use of such Prospectus and each amendment or supplement
thereto by each of the selling Holders in connection with the offering and sale of the Registrable Securities covered by such Prospectus
and any amendment or supplement thereto, except after the giving of any notice pursuant to Section 3(d).

 

(h)
 Prior to any resale of Registrable Securities by a Holder, use its commercially reasonable efforts to register or qualify or cooperate
with the selling Holders in connection with the registration or qualification (or exemption from the Registration or qualification) of
such Registrable Securities for the resale by the Holder under the securities or Blue Sky laws of such jurisdictions within the United
States as any Holder reasonably requests in writing, to keep each registration or qualification (or exemption therefrom) effective during
the Effectiveness Period and to do any and all other acts or things reasonably necessary to enable the disposition in such jurisdictions
of the Registrable Securities covered by each Registration Statement, provided that the Company shall not be required to qualify generally
to do business in any jurisdiction where it is not then so qualified, subject the Company to any material tax in any such jurisdiction
where it is not then so subject or file a general consent to service of process in any such jurisdiction.

 

(i) If requested
by a Holder, cooperate with such Holder to facilitate the timely preparation and delivery of certificates representing Registrable Securities
to be delivered to a transferee pursuant to a Registration Statement, which certificates shall be free, to the extent permitted by the
Purchase Agreement, of all restrictive legends, and to enable such Registrable Securities to be in such denominations and registered
in such names as any such Holder may request.

 

(j) Upon
the occurrence of any event contemplated by Section 3(d), as promptly as reasonably possible under the circumstances taking into account
the Company’s good faith assessment of any adverse consequences to the Company and its stockholders of the premature disclosure
of such event, prepare a supplement or amendment, including a post-effective amendment, to a Registration Statement or a supplement to
the related Prospectus or any document incorporated or deemed to be incorporated therein by reference, and file any other required document
so that, as thereafter delivered, neither a Registration Statement nor such Prospectus will contain an untrue statement of a material
fact or omit to state a material fact required to be stated therein or necessary to make the statements therein, in light of the circumstances
under which they were made, not misleading. If the Company notifies the Holders in accordance with clauses (iii) through (vi) of Section
3(d) above to suspend the use of any Prospectus until the requisite changes to such Prospectus have been made, then the Holders shall
suspend use of such Prospectus. The Company will use its best efforts to ensure that the use of the Prospectus may be resumed as promptly
as is practicable. The Company shall be entitled to exercise its right under this Section 3(j) to suspend the availability of a Registration
Statement and Prospectus, subject to the payment of partial liquidated damages otherwise required pursuant to Section 2(d), for a period
not to exceed 60 calendar days (which need not be consecutive days) in any 12-month period.

 

(k)
Otherwise use commercially reasonable efforts to comply with all applicable rules and regulations of the Commission under the Securities
Act and the Exchange Act, including, without limitation, Rule 172 under the Securities Act, file any final Prospectus, including any supplement
or amendment thereof, with the Commission pursuant to Rule 424 under the Securities Act, promptly inform the Holders in writing if, at
any time during the Effectiveness Period, the Company does not satisfy the conditions specified in Rule 172 and, as a result thereof,
the Holders are required to deliver a Prospectus in connection with any disposition of Registrable Securities and take such other actions
as may be reasonably necessary to facilitate the registration of the Registrable Securities hereunder.

 

    7

     

    

 

(l) The Company
shall use its best efforts to maintain eligibility for use of Form S-3 (or any successor form thereto) for the registration of the resale
of Registrable Securities, to the extent available at the time of entry into this Agreement, or the extent it becomes available hereafter.

 

(m)
The Company may require each selling Holder to furnish to the Company a certified statement as to the number of shares of Common
Stock beneficially owned by such Holder and, if required by the Commission, the natural persons thereof that have voting and dispositive
control over the shares. During any periods that the Company is unable to meet its obligations hereunder with respect to the registration
of the Registrable Securities solely because any Holder fails to furnish such information within three Trading Days of the Company’s
request, any liquidated damages that are accruing at such time as to such Holder only shall be tolled and any Event that may otherwise
occur solely because of such delay shall be suspended as to such Holder only, until such information is delivered to the Company.

 

4.  Registration
Expenses. All fees and expenses incident to the performance of or compliance with, this Agreement by the Company shall be borne by
the Company whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to
in the foregoing sentence shall include, without limitation, (i) all registration and filing fees (including, without limitation, fees
and expenses of the Company’s counsel and independent registered public accountants) (A) with respect to filings made with the Commission,
(B) with respect to filings required to be made with any Trading Market on which the Common Stock is then listed for trading, and (C)
in compliance with applicable state securities or Blue Sky laws reasonably agreed to by the Company in writing (including, without limitation,
fees and disbursements of counsel for the Company in connection with Blue Sky qualifications or exemptions of the Registrable Securities),
(ii) printing expenses (including, without limitation, expenses of printing certificates for Registrable Securities), (iii) messenger,
telephone and delivery expenses, (iv) fees and disbursements of counsel for the Company, (v) Securities Act liability insurance, if the
Company so desires such insurance, and (vi) fees and expenses of all other Persons retained by the Company in connection with the consummation
of the transactions contemplated by this Agreement. In addition, the Company shall be responsible for all of its internal expenses incurred
in connection with the consummation of the transactions contemplated by this Agreement (including, without limitation, all salaries and
expenses of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses
incurred in connection with the listing of the Registrable Securities on any securities exchange as required hereunder. In no event shall
the Company be responsible for any broker or similar commissions of any Holder or, except to the extent provided for in the Transaction
Documents, any legal fees or other costs of the Holders.

 

5.  Indemnification.

 

(a)
Indemnification by the Company. The Company shall, notwithstanding any termination of this Agreement, indemnify and hold
harmless each Holder, the officers, directors, members, partners, agents, brokers (including brokers who offer and sell Registrable Securities
as principal as a result of a pledge or any failure to perform under a margin call of Common Stock), investment advisors and employees
(and any other Persons with a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any
other title) of each of them, each Person who controls any such Holder (within the meaning of Section 15 of the Securities Act or Section
20 of the Exchange Act) and the officers, directors, members, stockholders, partners, agents and employees (and any other Persons with
a functionally equivalent role of a Person holding such titles, notwithstanding a lack of such title or any other title) of each such
controlling Person, to the fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities,
costs (including, without limitation, reasonable attorneys’ fees) and expenses (collectively, “Losses”), as incurred,
arising out of or relating to (1) any untrue or alleged untrue statement of a material fact contained in a Registration Statement, any
Prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or
relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein
(in the case of any Prospectus or supplement thereto, in light of the circumstances under which they were made) not misleading or (2)
any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or
regulation thereunder, in connection with the performance of its obligations under this Agreement, except to the extent, but only to the
extent, that (i) such untrue statements or omissions are based solely upon information regarding such Holder furnished in writing to the
Company by such Holder expressly for use therein, or to the extent that such information relates to such Holder or such Holder’s
proposed method of distribution of Registrable Securities and was reviewed and expressly approved in writing by such Holder expressly
for use in a Registration Statement, such Prospectus or in any amendment or supplement thereto (it being understood that the Holder has
approved Annex A hereto for this purpose) or (ii) in the case of an occurrence of an event of the type specified in Section 3(d)(iii)-(vi),
the use by such Holder of an outdated, defective or otherwise unavailable Prospectus after the Company has notified such Holder in writing
that the Prospectus is outdated, defective or otherwise unavailable for use by such Holder and prior to the receipt by such Holder of
the Advice contemplated in Section 6(c). The Company shall notify the Holders promptly of the institution, threat or assertion of any
Proceeding arising from or in connection with the transactions contemplated by this Agreement of which the Company is aware. Such indemnity
shall remain in full force and effect regardless of any investigation made by or on behalf of such indemnified person and shall survive
the transfer of any Registrable Securities by any of the Holders in accordance with Section 6(f).

 

    8

     

    

 

(b)
Indemnification by Holders. Each Holder shall, severally and not jointly, indemnify and hold harmless the Company, its directors,
officers, agents and employees, each Person who controls the Company (within the meaning of Section 15 of the Securities Act and Section
20 of the Exchange Act), and the directors, officers, agents or employees of such controlling Persons, to the fullest extent permitted
by applicable law, from and against all Losses, as incurred, to the extent arising out of or based solely upon: any untrue or alleged
untrue statement of a material fact contained in any Registration Statement, any Prospectus, or in any amendment or supplement thereto
or in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be
stated therein or necessary to make the statements therein (in the case of any Prospectus or supplement thereto, in light of the circumstances
under which they were made) not misleading (i) to the extent, but only to the extent, that such untrue statement or omission is contained
in any information so furnished in writing by such Holder to the Company expressly for inclusion in such Registration Statement or such
Prospectus or (ii) to the extent, but only to the extent, that such information relates to such Holder’s information provided in
the Selling Stockholder Questionnaire or the proposed method of distribution of Registrable Securities and was reviewed and expressly
approved in writing by such Holder expressly for use in a Registration Statement (it being understood that the Holder has approved Annex
A hereto for this purpose), such Prospectus or in any amendment or supplement thereto. In no event shall the liability of a selling Holder
be greater in amount than the dollar amount of the proceeds (net of all expenses paid by such Holder in connection with any claim relating
to this Section 5 and the amount of any damages such Holder has otherwise been required to pay by reason of such untrue statement or omission)
received by such Holder upon the sale of the Registrable Securities included in the Registration Statement giving rise to such indemnification
obligation.

 

(c)
Conduct of Indemnification Proceedings. If any Proceeding shall be brought or asserted against any Person entitled to indemnity
hereunder (an “Indemnified Party”), such Indemnified Party shall promptly notify the Person from whom indemnity is
sought (the “Indemnifying Party”) in writing, and the Indemnifying Party shall have the right to assume the defense
thereof, including the employment of counsel reasonably satisfactory to the Indemnified Party and the payment of all fees and expenses
incurred in connection with defense thereof, provided that the failure of any Indemnified Party to give such notice shall not relieve
the Indemnifying Party of its obligations or liabilities pursuant to this Agreement, except (and only) to the extent that it shall be
finally determined by a court of competent jurisdiction (which determination is not subject to appeal or further review) that such failure
shall have materially and adversely prejudiced the Indemnifying Party.

 

An Indemnified
Party shall have the right to employ separate counsel in any such Proceeding and to participate in the defense thereof, but the fees and
expenses of such counsel shall be at the expense of such Indemnified Party or Parties unless: (1) the Indemnifying Party has agreed in
writing to pay such fees and expenses, (2) the Indemnifying Party shall have failed promptly to assume the defense of such Proceeding
and to employ counsel reasonably satisfactory to such Indemnified Party in any such Proceeding, or (3) the named parties to any such Proceeding
(including any impleaded parties) include both such Indemnified Party and the Indemnifying Party, and counsel to the Indemnified Party
shall reasonably believe that a material conflict of interest is likely to exist if the same counsel were to represent such Indemnified
Party and the Indemnifying Party (in which case, if such Indemnified Party notifies the Indemnifying Party in writing that it elects to
employ separate counsel at the expense of the Indemnifying Party, the Indemnifying Party shall not have the right to assume the defense
thereof and the reasonable fees and expenses of no more than one separate counsel shall be at the expense of the Indemnifying Party).
The Indemnifying Party shall not be liable for any settlement of any such Proceeding effected without its written consent, which consent
shall not be unreasonably withheld or delayed. No Indemnifying Party shall, without the prior written consent of the Indemnified Party,
effect any settlement of any pending Proceeding in respect of which any Indemnified Party is a party, unless such settlement includes
an unconditional release of such Indemnified Party from all liability on claims that are the subject matter of such Proceeding.

 

    9

     

    

 

Subject to the
terms of this Agreement, all reasonable fees and expenses of the Indemnified Party (including reasonable fees and expenses to the extent
incurred in connection with investigating or preparing to defend such Proceeding in a manner not inconsistent with this Section) shall
be paid to the Indemnified Party, as incurred, within ten Trading Days of written notice thereof to the Indemnifying Party, provided that
the Indemnified Party shall promptly reimburse the Indemnifying Party for that portion of such fees and expenses applicable to such actions
for which such Indemnified Party is finally determined by a court of competent jurisdiction (which determination is not subject to appeal
or further review) not to be entitled to indemnification hereunder.

 

(d)
Contribution. If the indemnification under Section 5(a) or 5(b) is unavailable to an Indemnified Party or insufficient to
hold an Indemnified Party harmless for any Losses, then each Indemnifying Party shall contribute to the amount paid or payable by such
Indemnified Party, in such proportion as is appropriate to reflect the relative fault of the Indemnifying Party and Indemnified Party
in connection with the actions, statements or omissions that resulted in such Losses as well as any other relevant equitable considerations.
The relative fault of such Indemnifying Party and Indemnified Party shall be determined by reference to, among other things, whether any
action in question, including any untrue or alleged untrue statement of a material fact or omission or alleged omission of a material
fact, has been taken or made by, or relates to information supplied by, such Indemnifying Party or Indemnified Party, and the parties’
relative intent, knowledge, access to information and opportunity to correct or prevent such action, statement or omission. The amount
paid or payable by a party as a result of any Losses shall be deemed to include, subject to the limitations set forth in this Agreement,
any reasonable attorneys’ or other fees or expenses incurred by such party in connection with any Proceeding to the extent such
party would have been indemnified for such fees or expenses if the indemnification provided for in this Section was available to such
party in accordance with its terms.

 

The parties hereto
agree that it would not be just and equitable if contribution pursuant to this Section 5(d) were determined by pro rata allocation or
by any other method of allocation that does not take into account the equitable considerations referred to in the immediately preceding
paragraph. In no event shall the contribution obligation of a Holder of Registrable Securities be greater in amount than the dollar amount
of the proceeds (net of all expenses paid by such Holder in connection with any claim relating to this Section 5 and the amount of any
damages such Holder has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission)
received by it upon the sale of the Registrable Securities giving rise to such contribution obligation.

 

The indemnity and
contribution agreements contained in this Section are in addition to any liability that the Indemnifying Parties may have to the Indemnified
Parties.

 
6. Miscellaneous.

 

    10

     

    

 

(a) Remedies. In the
event of a breach by the Company or by a Holder of any of their respective obligations under this Agreement, each Holder or the Company,
as the case may be, in addition to being entitled to exercise all rights granted by law and under this Agreement, including recovery
of damages, shall be entitled to specific performance of its rights under this Agreement. Each of the Company and each Holder agrees
that monetary damages would not provide adequate compensation for any losses incurred by reason of a breach by it of any of the provisions
of this Agreement and hereby further agrees that, in the event of any action for specific performance in respect of such breach, it shall
not assert or shall waive the defense that a remedy at law would be adequate.

 

(b) No Piggyback on
Registrations; Prohibition on Filing Other Registration Statements. Except as set forth on Schedule 6(b) attached hereto,
neither the Company nor any of its security holders (other than the Holders in such capacity pursuant hereto) may include securities
of the Company in any Registration Statements other than the Registrable Securities. Except as set forth on Schedule 6(b), the
Company shall not file any other registration statements until all Registrable Securities are registered pursuant to a Registration
Statement that is declared effective by the Commission, provided that this Section 6(b) shall not prohibit the Company from filing
amendments to registration statements filed prior to the date of this Agreement so long as no new securities are registered on any
such existing registration statements.

 

(c) Discontinued
Disposition. By its acquisition of Registrable Securities, each Holder agrees that, upon receipt of a notice from the Company of
the occurrence of any event of the kind described in Section 3(d)(iii) through (vi), such Holder will forthwith discontinue
disposition of such Registrable Securities under a Registration Statement until it is advised in writing (the
“Advice”) by the Company that the use of the applicable Prospectus (as it may have been supplemented or amended)
may be resumed. The Company will use its best efforts to ensure that the use of the Prospectus may be resumed as promptly as is
practicable. The Company agrees and acknowledges that any periods during which the Holder is required to discontinue the disposition
of the Registrable Securities hereunder shall be subject to the provisions of Section 2(d).

 

(d) Amendments and
Waivers. The provisions of this Agreement, including the provisions of this sentence, may not be amended, modified or
supplemented, and waivers or consents to departures from the provisions hereof may not be given, unless the same shall be in writing
and signed by the Company and the Holders of 50.1% or more of the then outstanding Registrable Securities (for purposes of
clarification, this includes any Registrable Securities issuable upon exercise or conversion of any Security), provided that, if any
amendment, modification or waiver disproportionately and adversely impacts a Holder (or group of Holders), the consent of such
disproportionately impacted Holder (or group of Holders) shall be required. If a Registration Statement does not register all of the
Registrable Securities pursuant to a waiver or amendment done in compliance with the previous sentence, then the number of
Registrable Securities to be registered for each Holder shall be reduced pro rata among all Holders and each Holder shall have the
right to designate which of its Registrable Securities shall be omitted from such Registration Statement. Notwithstanding the
foregoing, a waiver or consent to depart from the provisions hereof with respect to a matter that relates exclusively to the rights
of a Holder or some Holders and that does not directly or indirectly affect the rights of other Holders may be given only by such
Holder or Holders of all of the Registrable Securities to which such waiver or consent relates; provided, however,
that the provisions of this sentence may not be amended, modified, or supplemented except in accordance with the provisions of the
first sentence of this Section 6(d). No consideration shall be offered or paid to any Person to amend or consent to a waiver or
modification of any provision of this Agreement unless the same consideration also is offered to all of the parties to this
Agreement.

 

(e) Notices. Any
and all notices or other communications or deliveries required or permitted to be provided hereunder shall be delivered as set forth
in the Purchase Agreement.

 

(f) Successors and
Assigns. This Agreement shall inure to the benefit of and be binding upon the successors and permitted assigns of each of the
parties and shall inure to the benefit of each Holder. The Company may not assign (except by merger) its rights or obligations
hereunder without the prior written consent of all of the Holders of the then outstanding Registrable Securities. Each Holder may
assign their respective rights hereunder in the manner and to the Persons as permitted under Section 5.7 of the Purchase
Agreement.

 

    11

     

    

 

(g) No Inconsistent
Agreements. Neither the Company nor any of its Subsidiaries has entered, as of the date hereof, nor shall the Company or any of
its Subsidiaries, on or after the date of this Agreement, enter into any agreement with respect to its securities, that would have
the effect of impairing the rights granted to the Holders in this Agreement or otherwise conflicts with the provisions hereof.
Except as set forth on Schedule 6(i), neither the Company nor any of its Subsidiaries has previously entered into any
agreement granting any registration rights with respect to any of its securities to any Person that have not been satisfied in
full.

 

(h) Execution and
Counterparts. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered
one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other
party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by
facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and
binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such
facsimile or “.pdf” signature page were an original thereof.

 

(i) Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be determined
in accordance with the provisions of the Purchase Agreement.

 

(j) Cumulative
Remedies. The remedies provided herein are cumulative and not exclusive of any other remedies provided by law.

 

(k) Severability.
If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be invalid,
illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in
full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they
would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter
declared invalid, illegal, void or unenforceable.

 

(l) Headings. The
headings in this Agreement are for convenience only, do not constitute a part of the Agreement and shall not be deemed to limit or
affect any of the provisions hereof.

 

(m) Independent
Nature of Holders’ Obligations and Rights. The obligations of each Holder hereunder are several and not joint with the
obligations of any other Holder hereunder, and no Holder shall be responsible in any way for the performance of the obligations of
any other Holder hereunder. Nothing contained herein or in any other agreement or document delivered at any closing, and no action
taken by any Holder pursuant hereto or thereto, shall be deemed to constitute the Holders as a partnership, an association, a joint
venture or any other kind of group or entity, or create a presumption that the Holders are in any way acting in concert or as a
group or entity with respect to such obligations or the transactions contemplated by this Agreement or any other matters, and the
Company acknowledges that the Holders are not acting in concert or as a group, and the Company shall not assert any such claim, with
respect to such obligations or transactions. Each Holder shall be entitled to protect and enforce its rights, including without
limitation the rights arising out of this Agreement, and it shall not be necessary for any other Holder to be joined as an
additional party in any proceeding for such purpose. The use of a single agreement with respect to the obligations of the Company
contained was solely in the control of the Company, not the action or decision of any Holder, and was done solely for the
convenience of the Company and not because it was required or requested to do so by any Holder. It is expressly understood and
agreed that each provision contained in this Agreement is between the Company and a Holder, solely, and not between the Company and
the Holders collectively and not between and among Holders.

 

********************

 

(Signature
Pages Follow)

 

    12

     

    

 

IN WITNESS WHEREOF, the parties
have executed this Registration Rights Agreement as of the date first written above.

 

	 	180 life Sciences corp.
	 	 
	 	By:	 
	 	 	Name:	 
	 	 	Title:	 

 

[SIGNATURE PAGE OF HOLDERS FOLLOWS]

 

     

     

    

 

[SIGNATURE
PAGE OF HOLDERS TO 180 Life Sciences corp. RRA]

 

	Name of Holder:	 	 
	 	 	 
	Signature of Authorized Signatory of Holder:	 	 
	 	 	 
	Name of Authorized Signatory:	 	 
	 	 	 
	Title of Authorized Signatory:	 	 

 

[SIGNATURE PAGES CONTINUE]

 

     

     

    

 

Annex A

 

Plan of Distribution

 

Each Selling Stockholder (the
“Selling Stockholders”) of the securities and any of their pledgees, assignees and successors-in-interest may, from
time to time, sell any or all of their securities covered hereby on the Trading Market or any other stock exchange, market or trading
facility on which the securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder
may use any one or more of the following methods when selling securities:

 

		●	ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;

 

		●	block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the
block as principal to facilitate the transaction;

 

		●	purchases by a broker-dealer as principal and resale by the broker-dealer for its account;

 

		●	an exchange distribution in accordance with the rules of the applicable exchange;

 

		●	privately negotiated transactions;

 

		●	settlement of short sales;

 

		●	in transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities at a
stipulated price per security;

 

		●	through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;

 

		●	a combination of any such methods of sale; or

 

		●	any other method permitted pursuant to applicable law.

 

The Selling Stockholders may
also sell securities under Rule 144 or any other exemption from registration under the Securities Act of 1933, as amended (the “Securities
Act”), if available, rather than under this prospectus.

 

Broker-dealers engaged by
the Selling Stockholders may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts
from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts
to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a
customary brokerage commission in compliance with FINRA Rule 2121; and in the case of a principal transaction a markup or markdown in
compliance with FINRA Rule 2121.

 

    A-1

     

    

 

In connection with the sale
of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers or other financial
institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling
Stockholders may also sell securities short and deliver these securities to close out their short positions, or loan or pledge the securities
to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with
broker-dealers or other financial institutions or create one or more derivative securities which require the delivery to such broker-dealer
or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution
may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction).

 

The Selling Stockholders and
any broker-dealers or agents that are involved in selling the securities may be deemed to be “underwriters” within the meaning
of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any
profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities
Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly
or indirectly, with any person to distribute the securities.

 

The Company is required to
pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify
the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.

 

We agreed to keep this prospectus
effective until the earlier of (i) the date on which the securities may be resold by the Selling Stockholders without registration and
without regard to any volume or manner-of-sale limitations by reason of Rule 144, without the requirement for the Company to be in compliance
with the current public information under Rule 144 under the Securities Act or any other rule of similar effect or (ii) all of the securities
have been sold pursuant to this prospectus or Rule 144 under the Securities Act or any other rule of similar effect. The resale securities
will be sold only through registered or licensed brokers or dealers if required under applicable state securities laws. In addition, in
certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable
state or an exemption from the registration or qualification requirement is available and is complied with.

 

Under applicable rules and
regulations under the Exchange Act, any person engaged in the distribution of the resale securities may not simultaneously engage in market
making activities with respect to the common stock for the applicable restricted period, as defined in Regulation M, prior to the commencement
of the distribution. In addition, the Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules
and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the common stock by the Selling
Stockholders or any other person. We will make copies of this prospectus available to the Selling Stockholders and have informed them
of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance with Rule
172 under the Securities Act).

 

    A-2

     

    

 

SELLING SHAREHOLDERS

 

The common stock being offered
by the selling shareholders are those previously issued to the selling shareholders, and those issuable to the selling shareholders, upon
exercise of the warrants. For additional information regarding the issuances of those shares of common stock and warrants, see “Private
Placement of Shares of Common Stock and Warrants” above. We are registering the shares of common stock in order to permit the selling
shareholders to offer the shares for resale from time to time. Except for the ownership of the shares of common stock and the warrants,
the selling shareholders have not had any material relationship with us within the past three years.

 

The table below lists the
selling shareholders and other information regarding the beneficial ownership of the shares of common stock by each of the selling shareholders.
The second column lists the number of shares of common stock beneficially owned by each selling shareholder, based on its ownership of
the shares of common stock and warrants, as of ________, 2021, assuming exercise of the warrants held by the selling shareholders on that
date, without regard to any limitations on exercises.

 

The third column lists the
shares of common stock being offered by this prospectus by the selling shareholders.

 

In accordance with the terms
of a registration rights agreement with the selling shareholders, this prospectus generally covers the resale of the sum of (i) the number
of shares of common stock issued to the selling shareholders in the “Private Placement of Shares of Common Stock and Warrants”
described above and (ii) the maximum number of shares of common stock issuable upon exercise of the related warrants, determined as if
the outstanding warrants were exercised in full as of the trading day immediately preceding the date this registration statement was initially
filed with the SEC, each as of the trading day immediately preceding the applicable date of determination and all subject to adjustment
as provided in the registration right agreement, without regard to any limitations on the exercise of the warrants. The fourth column
assumes the sale of all of the shares offered by the selling shareholders pursuant to this prospectus.

 

Under the terms of the warrants,
a selling shareholder may not exercise the warrants to the extent such exercise would cause such selling shareholder, together with its
affiliates and attribution parties, to beneficially own a number of shares of common stock which would exceed 4.99% or 9.99%, as applicable,
of our then outstanding common stock following such exercise, excluding for purposes of such determination shares of common stock issuable
upon exercise of such warrants which have not been exercised. The number of shares in the second and fourth columns do not reflect this
limitation. The selling shareholders may sell all, some or none of their shares in this offering. See "Plan of Distribution."

 

    A-3

     

    

 

	

Name of Selling Shareholder	Number of shares of

 Common Stock Owned

 Prior to Offering	Maximum Number of 

shares of Common Stock 

to be Sold Pursuant to this

 Prospectus	Number of shares of

 Common Stock Owned

 After Offering

 

    A-4

     

    

 

Annex C

 

180
Life Sciences Corp.

 

Selling Stockholder Notice and Questionnaire

 

The undersigned beneficial
owner of common stock (the “Registrable Securities”) of 180 Life Sciences Corp., a Delaware corporation (the “Company”),
understands that the Company has filed or intends to file with the Securities and Exchange Commission (the “Commission”)
a registration statement (the “Registration Statement”) for the registration and resale under Rule 415 of the Securities
Act of 1933, as amended (the “Securities Act”), of the Registrable Securities, in accordance with the terms of the
Registration Rights Agreement (the “Registration Rights Agreement”) to which this document is annexed. A copy of the
Registration Rights Agreement is available from the Company upon request at the address set forth below. All capitalized terms not otherwise
defined herein shall have the meanings ascribed thereto in the Registration Rights Agreement.

 

Certain legal consequences
arise from being named as a selling stockholder in the Registration Statement and the related prospectus. Accordingly, holders and beneficial
owners of Registrable Securities are advised to consult their own securities law counsel regarding the consequences of being named or
not being named as a selling stockholder in the Registration Statement and the related prospectus.

 

NOTICE

 

The undersigned
beneficial owner (the “Selling Stockholder”) of Registrable Securities hereby elects to include the Registrable
Securities owned by it in the Registration Statement. The undersigned hereby provides the following information to the Company and
represents and warrants that such information is accurate:

 

    C-1

     

    

 

QUESTIONNAIRE

 

		1.	Name.

 

		(a)	Full Legal Name of Selling Stockholder

 

	 	 

 

		(b)	Full Legal Name of Registered Holder (if not the same as (a) above) through which Registrable Securities
are held:

 

	 	 

	

 

		(c)	Full Legal Name of Natural Control Person (which means a natural person who directly or indirectly alone
or with others has power to vote or dispose of the securities covered by this Questionnaire):

 

	 	 
	 

 

2. Address for Notices to Selling Stockholder:

 

	 
	 
	 
	Telephone:	 
	Fax:	 
	Contact Person:	 

 

3. Broker-Dealer Status:

 

		(a)	Are you a broker-dealer?

 

Yes
☐         No ☐

 

		(b)	If “yes” to Section 3(a), did you receive your Registrable Securities as compensation for
investment banking services to the Company?

 

Yes ☐         No ☐

 

		Note:	If “no” to Section 3(b), the Commission’s
staff has indicated that you should be identified as an underwriter in the Registration Statement.

 

    C-2

     

    

 

		(c)	Are you an affiliate of a broker-dealer?

 

Yes ☐         No ☐

 

		(d)	If you are an affiliate of a broker-dealer, do you certify that you purchased the Registrable Securities
in the ordinary course of business, and at the time of the purchase of the Registrable Securities to be resold, you had no agreements
or understandings, directly or indirectly, with any person to distribute the Registrable Securities?

 

Yes ☐         No ☐

 

		Note:	If “no” to Section 3(d), the Commission’s
staff has indicated that you should be identified as an underwriter in the Registration Statement.

 

4. Beneficial Ownership of Securities
of the Company Owned by the Selling Stockholder.

 

Except as set forth below in this
Item 4, the undersigned is not the beneficial or registered owner of any securities of the Company other than the securities issuable
pursuant to the Purchase Agreement.

 

		(a)	Type and Amount of other securities beneficially owned by the Selling Stockholder:

	 
	 

 

    C-3

     

    

 

5. Relationships with the Company:

 

Except as set forth below, neither
the undersigned nor any of its affiliates, officers, directors or principal equity holders (owners of 5% of more of the equity securities
of the undersigned) has held any position or office or has had any other material relationship with the Company (or its predecessors or
affiliates) during the past three years.

 

State any exceptions here:

	 
	 

 

The undersigned agrees to
promptly notify the Company of any material inaccuracies or changes in the information provided herein that may occur subsequent to the
date hereof at any time while the Registration Statement remains effective; provided, that the undersigned shall not be required to notify
the Company of any changes to the number of securities held or owned by the undersigned or its affiliates.

 

By
signing below, the undersigned consents to the disclosure of the information contained herein in its answers to Items 1 through 5 and
the inclusion of such information in the Registration Statement and the related prospectus and any amendments or supplements thereto.
The undersigned understands that such information will be relied upon by the Company in connection with the preparation or amendment of
the Registration Statement and the related prospectus and any amendments or supplements thereto.

 

IN WITNESS WHEREOF the undersigned,
by authority duly given, has caused this Notice and Questionnaire to be executed and delivered either in person or by its duly authorized
agent.

 

	Date:	 	 	Beneficial Owner:	 

 

	 	By:	 
	 	 	Name:	 
	 	 	Title:	 

 

PLEASE FAX A COPY (OR EMAIL A .PDF COPY) OF
THE COMPLETED AND EXECUTED NOTICE AND QUESTIONNAIRE TO:

 

 

C-4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}]]